Insulet (MEX:PODD) Moat Score: 7/10 (As of Jul. 02, 2026)


MEX:PODD Insulet Corp MEX:PODD
75 GF Score
Price MXN2,780.00
GF Value MXN6,893.57
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Moat Score?

Insulet MEX:PODD 75 Moat Score is 7 as of Jul. 02, 2026. GuruFocus rates MEX:PODD with a GF Score™ of 75/100 and a GF Value™ of MXN6,893.57 (Significantly Undervalued). Among 846 Medical Devices & Instruments companies, Insulet ranks better than 98.94% on this metric.

Insulet has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Insulet has Wide Moat: Insulet Corp has an entry-level wide moat due to its innovative insulin delivery systems, strong brand, and customer loyalty. The company benefits from significant switching costs and proprietary technology, providing durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Insulet might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Insulet  (MEX:PODD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Insulet Moat Score Related Terms

MEX:PODD vs GMED, PEN, BRKR: Moat Score Comparison

For the Medical Devices subindustry, Insulet's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insulet Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Moat Score distribution charts can be found below:

* The bar in red indicates where Insulet's Moat Score falls into.


MEX:PODD
75GF Score
Insulet Corp MEX:PODD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Insulet (MEX:PODD) has a Moat Score of 7 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Insulet ranks #9 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is Insulet's Moat Score too high?
Insulet's current Moat Score is 7. Based on the distribution chart, Insulet ranks #9 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Insulet has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Moat Score compare to GMED and PEN?
According to the Medical Devices & Instruments industry distribution chart, Insulet ranks #9 out of 846 companies for Moat Score. This places Insulet in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Insulet's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (MEX:PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN6,893.57, compared to a current price of MXN2,780.00 — trading 59.7% below its estimated fair value. The current Moat Score is 7. Insulet's overall GF Score™ is 75/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Insulet (MEX:PODD), the current Moat Score is 7 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (MEX:PODD) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of MXN2,780.00 is trading 59.7% below its estimated GF Value™ of MXN6,893.57. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for MEX:PODD:

  • Moat Score: 7
  • GF Value™: MXN6,893.57 vs. price of MXN2,780.00 (59.7% below fair value)
  • GF Score™: 75/100

No single metric tells the full story. See the MEX:PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
75GF Score

Get the complete analysis for MEX:PODD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,780.00
Price
MXN6,893.57
GF Value